



**CLL SOCIETY**

*Smart Patients Get Smart Care™*

**YOUR  
MEDICARE GUIDE:  
TACKLING COSTS  
AND ANSWERING  
YOUR QUESTIONS**

**SEPTEMBER 9, 2024**

11:30 AM PT, 12:30 AM MT

1:30 AM CT, 2:30 PM ET

**This Program is Made Possible  
Through Generous Donors  
LIKE YOU**



# SPEAKERS



**Saira Sultan**

JD  
(SPEAKER)

President & CEO  
Connect 4 Strategies  
Director of Government Affairs & Public Policy  
CLL Society



**Kay Scanlan**

JD  
(SPEAKER)

Principal  
Consilium Strategies



**Giselle Bleeker**

MBA, MPH  
(SPEAKER)

Certified  
Medicare Navigator



# MEDICARE

**PART A**

**HOSPITAL  
INPATIENT**

**PART B**

**HOSPITAL  
OUTPATIENT &  
PHYSICIAN  
OFFICES**

**PART D**

**PRESCRIPTION  
DRUGS**

**PART C**

**“MEDICARE  
ADVANTAGE”**

**Parts A+B+D**



# POLL QUESTIONS

**PART D**

**PRESCRIPTION  
DRUGS**

**PART C**

**“MEDICARE  
ADVANTAGE”**

**Parts A+B+D**




# NEW INFLATION REDUCTION ACT ("IRA") LAW AND IMPLEMENTATION

Congress passed a law known as the **Inflation Reduction Act or "IRA"** -- making some structural changes to the Medicare Part D and Medicare Advantage programs, and requiring direct government price negotiation in Medicare.

- The **Centers for Medicare and Medicaid Services ("CMS")** administers the Medicare program.
- CMS has created an entire division to implement the new law.
- We have spent significant time analyzing the implications of this law for our community.



# COMPONENTS OF THE NEW LAW FOR DISCUSSION TODAY





# THE MOST TALKED ABOUT PROVISION OF THE IRA:

**DIRECT PRICE NEGOTIATION**




# NEW PRICES

NEW PRICES AFTER NEGOTIATION OF THE FIRST TEN DRUGS SELECTED FOR MEDICARE PRICE NEGOTIATION

Under the Biden-Harris Administration

DRUG	LIST PRICE	NEGOTIATED PRICE
<b>ELIQUIS</b> <i>For Blood Clots</i>	\$521	\$231
<b>JARDIANCE</b> <i>For Diabetes, Heart Failure, Chronic Kidney Disease</i>	\$573	\$197
<b>XARELTO</b> <i>For Blood Clots and Coronary Artery Disease</i>	\$517	\$113
<b>JANUVIA</b> <i>For Diabetes</i>	\$527	\$178.50
<b>FARXIGA</b> <i>For Diabetes, Heart Failure, Kidney Disease</i>	\$628	\$295
<b>ENTRESTO</b> <i>For Heart Failure</i>	\$7,106	\$2,355
<b>IMBRUVICA</b> <i>For Blood Cancers</i>	\$14,934	\$9,319
<b>STELARA</b> <i>For Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis</i>	\$495	\$119
<b>FIASP</b> <i>FIASP FLEXTOUCH, FIASP PENFILL, NOVOLÓG, NOVOLÓG FLEXPEN, NOVOLÓG PENFILL</i> <i>For Diabetes</i>		

<b>IMBRUVICA</b> <i>For Blood Cancers</i>	\$14,934	\$9,319
--	----------	---------




# COMPONENTS OF THE INFLATION REDUCTION ACT FOR DISCUSSION TODAY

**OUT OF POCKET CAP**



# Changes to Medicare Part D for Brand-Name Drug Costs

Share of **brand-name drug** costs paid by: ● Enrollees ● Part D Plans ● Drug manufacturers ● Medicare




NOTE: OOP is out-of-pocket. The out-of-pocket spending threshold will be \$7,400 in 2023 and is projected to be \$7,750 in 2024 and \$8,100 in 2025, including what beneficiaries pay directly out of pocket and the value of the manufacturer discount on brand-name drugs in the coverage gap phase. These amounts translate to out-of-pocket spending of approximately \$3,100, \$3,250, and \$3,400 (based on brand-name drug use only).



# Changes to Medicare Part D for Brand-Name Drug Costs

Share of **brand-name drug** costs paid by: ● Enrollees ● Part D Plans ● Drug manufacturers ● Medicare




NOTE: OOP is out-of-pocket. The out-of-pocket spending threshold will be \$7,400 in 2023 and is projected to be \$7,750 in 2024 and \$8,100 in 2025, including what beneficiaries pay directly out of pocket and the value of the manufacturer discount on brand-name drugs in the coverage gap phase. These amounts translate to out-of-pocket spending of approximately \$3,100, \$3,250, and \$3,400 (based on brand-name drug use only).




# POLL QUESTION

Current law: 2023



# Changes to Medicare Part D for Brand-Name Drug Costs

Share of **brand-name drug** costs paid by: ● Enrollees ● Part D Plans ● Drug manufacturers ● Medicare




NOTE: OOP is out-of-pocket. The out-of-pocket spending threshold will be \$7,400 in 2023 and is projected to be \$7,750 in 2024 and \$8,100 in 2025, including what beneficiaries pay directly out of pocket and the value of the manufacturer discount on brand-name drugs in the coverage gap phase. These amounts translate to out-of-pocket spending of approximately \$3,100, \$3,250, and \$3,400 (based on brand-name drug use only).



# Changes to Medicare Part D for Brand-Name Drug Costs

Share of **brand-name drug** costs paid by: ● Enrollees ● Part D Plans ● Drug manufacturers ● Medicare



NOTE: OOP is out-of-pocket. The out-of-pocket spending threshold will be \$7,400 in 2023 and is projected to be \$7,750 in 2024 and \$8,100 in 2025, including what beneficiaries pay directly out of pocket and the value of the manufacturer discount on brand-name drugs in the coverage gap phase. These amounts translate to out-of-pocket spending of approximately \$3,100, \$3,250, and \$3,400 (based on brand-name drug use only).



# MEDICARE

**PART A**

**HOSPITAL  
INPATIENT**

**PART B**

**HOSPITAL  
OUTPATIENT &  
PHYSICIAN  
OFFICES**

**PART D**

**PRESCRIPTION  
DRUGS**

**PART C**

**“MEDICARE  
ADVANTAGE”**

**Parts A+B+D**





# AUDIENCE Q&A




# COMPONENTS OF THE INFLATION REDUCTION ACT FOR DISCUSSION TODAY

**“SMOOTHING”**



# POLL QUESTIONS



# “SMOOTHING” OR MEDICARE PRESCRIPTION PAYMENT PLAN (MP3)

- A new program allows patients to spread their OOP costs in both Medicare Part C and D across the plan year
  - One big detail: Congress caved to insurance companies on: *Patients Must Proactively Sign Up!*
- Like a monthly credit card payment or like running up a “tab” at a bar or restaurant?
  - No interest
  - High costs hitting mid-year and not benefitting as much
  - Monthly amount may keep changing
  - No dis-enrollment from the Part D or MA plan, just ‘smoothing’ program
- “Likely to Benefit”
- *Helpful Hints:* Enrollment on-line/confirmation; Payment by Check/Memo Line




# NEW PRICES

NEW PRICES AFTER NEGOTIATION OF THE FIRST TEN DRUGS SELECTED FOR MEDICARE PRICE NEGOTIATION

Under the Biden-Harris Administration

DRUG	LIST PRICE	NEGOTIATED PRICE
<b>ELIQUIS</b> <i>For Blood Clots</i>	\$521	\$231
<b>JARDIANCE</b> <i>For Diabetes, Heart Failure, Chronic Kidney Disease</i>	\$573	\$197
<b>XARELTO</b> <i>For Blood Clots and Coronary Artery Disease</i>	\$517	\$113
<b>JANUVIA</b> <i>For Diabetes</i>	\$527	\$178.50
<b>FARXIGA</b> <i>For Diabetes, Heart Failure, Kidney Disease</i>	\$628	\$295
<b>ENTRESTO</b> <i>For Heart Failure</i>	\$7,106	\$2,355
<b>IMBRUVICA</b> <i>For Blood Cancers</i>	\$14,934	\$9,319
<b>STELARA</b> <i>For Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis</i>	\$495	\$119
<b>FIASP</b> <i>FIASP FLEXTOUCH, FIASP PENFILL, NOVOLOG, NOVOLOG FLEXPEN, NOVOLOG PENFILL</i>		

<b>IMBRUVICA</b> <i>For Blood Cancers</i>	\$14,934	\$9,319
--	----------	---------



# THE CLL MEDICINE CABINET & 2025 OOP COSTS



- Acalabrutinib = \$2000 OOP
- Duvelisib = \$2,000 OOP
- **Ibrutinib = \$2,000 OOP**
- Idelalisib = \$2,000 OOP
- obinutuzumab = \$2,000 OOP
- Pirtobrutinib = \$2,000 OOP
- Rituximab = \$2,000 OOP
- Venetoclax = \$2,000 OOP
- Zanubrutinib = \$2,000 OOP



# MP3: CLL Society Fighting for Details that Support Our Patients

- **No auto enrollment in the first year, but allow auto-renewal after first opt-in (w/ notice to patients to opt out ...like traditional Medicare)**
- **Longer grace period**
- **Communication early and often, clear and simple, etc.**
- **Circumstances warranting rolling one year's obligations into next year**
- **Clearer communication that even missing grace period doesn't mean that if obligation is satisfied, you can't re-enroll**
- **Make appeals easier**
- **Require all Part D/MA plans to use uniform processes, forms, etc.**
- **Easy access on website?**
- **Annual reports – catch unusual drop out rates or other red flags for immediate remedial action**



# Broader Details Also Critical to Defend for Our Patients

- **Will patients have to “step” through Imbruvica first?**
- **Will patients be encouraged/incentivized/required to take anything but Imbruvica first?**
- **Will companies be discouraged from ongoing study of different combinations, dosage strengths, indications, etc.?**





# **SIGN UP IN 2025!**

**Follow CLL Society to stay updated!**



**CLL SOCIETY**

# STAY IN TOUCH IN 2025!

Tell us about your experience  
with the program too!



CLL SOCIETY

# AUDIENCE Q&A





# MEDICARE 101 WEBINAR

Join Triage Cancer for a free webinar on September 26, at 11:30am Central!

Learn about:

- The different “Parts” of Medicare
- Supplemental (Medigap) plans
- Enrollment periods
- How it works with other insurance
- Changes coming in 2025

We'll also show you how to compare Medicare plans using Triage Cancer's Medicare Options Comparison Worksheet.

**REGISTER NOW: [TRIAGECANCER.ORG/MEDICARE-2024](https://TRIAGECANCER.ORG/MEDICARE-2024)**

© 2024 Triage Cancer®



**SCAN TO REGISTER**



# THANK YOU FOR ATTENDING!

Please take a moment to complete our post-event survey,  
your feedback is important to us

If your question was not answered,  
please feel free to email: [support@cllsociety.org](mailto:support@cllsociety.org)

Join us for our next webinar,  
**BEYOND YOUR CLL DIAGNOSIS:  
COMPREHENSIVE HEALTH AND MANAGEMENT**  
on September 17<sup>th</sup>

CLL SOCIETY is invested in your long life. Please invest in  
the long life of the CLL SOCIETY by supporting our work:  
[cllsociety.org/donate-to-cll-society/](https://cllsociety.org/donate-to-cll-society/)

